Monday, August 31, 2026

Rivian Scraps 2027 Profit Goal, Joins Global Race for Autonomous Vehicle Dominance

Rivian Automotive has abandoned its 2027 profitability target to fund autonomous vehicle development, partnering with Uber Technologies in a strategic shift. The decision mirrors choices facing EV manufacturers worldwide as Chinese competitors like BYD and Xpeng advance autonomous capabilities while Western automakers balance short-term returns against AI mobility investments.

LM Salvado
LM Salvado

March 24, 2026

Rivian Scraps 2027 Profit Goal, Joins Global Race for Autonomous Vehicle Dominance
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Rivian Automotive withdrew its 2027 profitability target to fund autonomous vehicle development, joining a global competitive landscape where Chinese manufacturers already deploy advanced self-driving systems. The American EV maker is reallocating capital to autonomous technology infrastructure through a robotaxi partnership with Uber Technologies.

Uber's strategic investment in Rivian marks a return to autonomous vehicles after the ride-hailing giant sold its Uber ATG self-driving unit in 2020. That sale highlighted the capital intensity of in-house autonomous development, a challenge now facing automakers across North America, Europe, and Asia as they compete with China's rapidly advancing autonomous vehicle ecosystem.

Rivian's R2 vehicle platform may serve as the foundation for the Uber robotaxi collaboration, providing a deployment path through Uber's global ride-hailing network spanning 70 countries. The partnership structure differs from approaches in China, where companies like Baidu operate independent robotaxi services, and Europe, where regulatory frameworks remain fragmented across member states.

The profitability delay reflects strategic divergence in the global EV industry. Chinese manufacturers like BYD and Xpeng are already integrating advanced driver assistance systems while maintaining profitability through scale and vertical integration. Western automakers face pressure to match autonomous capabilities without China's manufacturing cost advantages or domestic market protection.

Rivian's choice prioritizes long-term positioning in AI-enabled mobility over near-term earnings, betting that autonomous technology will reshape transportation markets globally. The strategy carries risk as capital-intensive development timelines extend and competition intensifies from established automakers, technology companies, and well-funded Chinese competitors entering international markets.

Note: This article was generated from analytical data. Proper source citations cannot be included without access to original source documents.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com